JAK/HDAC-IN-2
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers.
For research use only. We do not sell to patients.
- CAS No.: 3029138-43-7
- Formula: C28H38N6O5S
- Molecular Weight:570.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
JAK2 5.32 nM (IC50) |
JAK1 27.15 nM (IC50) |
JAK3 594.8 nM (IC50) |
Tyk2 414.4 nM (IC50) |
HDAC 170 nM (IC50) |
HDAC1 340 nM (IC50) |
HDAC2 303 nM (IC50) |
HDAC3 58.7 nM (IC50) |
HDAC6 4.44 nM (IC50) |
HDAC10 116.1 nM (IC50) |
HDAC11 724.4 nM (IC50) |
HDAC4 >10000 nM (IC50) |
HDAC5 >10000 nM (IC50) |
HDAC7 >10000 nM (IC50) |
HDAC8 >10000 nM (IC50) |
HDAC9 >10000 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.73 μM
Compound: 21
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK-8 assay
|
[PMID: 37057760] |
| HEL | IC50 |
0.33 μM
Compound: 21
|
Antiproliferative activity against HEL cells incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against HEL cells incubated for 72 hrs by CCK-8 assay
|
[PMID: 37057760] |
| HeLa | IC50 |
2.88 μM
Compound: 21
|
Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK-8 assay
|
[PMID: 37057760] |
| HL-60 | IC50 |
2.58 μM
Compound: 21
|
Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK-8 assay
|
[PMID: 37057760] |
| K562 | IC50 |
1.87 μM
Compound: 21
|
Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK-8 assay
|
[PMID: 37057760] |
| MCF7 | IC50 |
1.83 μM
Compound: 21
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK-8 assay
|
[PMID: 37057760] |
| PC-3 | IC50 |
2.52 μM
Compound: 21
|
Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human PC-3 cells incubated for 72 hrs by CCK-8 assay
|
[PMID: 37057760] |
In Vitro
JAK/HDAC-IN-2 (compound 21) exhibits great antiproliferative activities against K562, HL-60, and HEL cells (IC50=1.87, 2.26, and 0.33 μM, respectively). JAK/HDAC-IN-2 inhibits the proliferation of four solid tumor cells, MCF-7, HeLa, A549, and PC-3 (IC50=1.83, 2.88, 0.73, and 2.52 μM, respectively)[1].
JAK/HDAC-IN-2 (1, 5 μM; 24 h) possesses excellent proapoptotic activity in HEL cells and moderate proapoptotic activity in A549 cells[1].
JAK/HDAC-IN-2 (1, 5 μM; 24 h) significantly induces the inhibition of histone deacetylation and STAT3 phosphorylation in hematological malignancy HEL cells as well as solid tumor A549 cells by inhibiting both HDAC and JAK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEL cells
-
Concentration:1, 5 μM
-
Incubation Time:24 h
-
Result:The apoptotic rates were 37.6% at 1 μM and 81.5% at 5 μM on HEL cells.
-
Cell Line:A549 and HEL cells
-
Concentration:1, 5 μM
-
Incubation Time:24 h
-
Result:Bviously upgraded the expression level of acetyl-H3 and acetyl-tubulin in A549 cells in a dose-dependent manner.
Reduced the expression level of p-STAT3-Tyr705.
In Vivo
Pharmacokinetic Parameters of LSD1-IN-14 in male Sprague-Dawley rats[1].
| IV (3 mg/kg) | PO (15 mg/kg) | |
| Tmax (h) | 2.912 | |
| Cmax (ng/mL) | 93.328 | |
| AUC0-t (ng/mL∗h) | 656.241 | 745.249 |
| t1/2 (h) | 0.128 | 2.084 |
| CL (L/ kg∗h) | 4.571 | 4.56 |
| Vss (L/kg) | 0.845 | |
| F (%) | 22.71% |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 nude mice[1]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneally; once a day for 18 consecutive days
-
Result:Prominently reduced the weight and volume of HEL and A549 xenografts.
Upgraded the expression level of acetyl-H3 as well as acetyl-tubulin and reduced the expression level of p-STAT3-Tyr705 in HEL as well as A549 xenograft tumor tissues.
Chemical Information
-
CAS No. 3029138-43-7
-
Molecular Weight 570.70
-
Formula C28H38N6O5S
-
SMILES
CC(NS(C1=CC(NC2=NC(NC3=CC=C(C=C3)OCCCCCCC(NO)=O)=NC=C2C)=CC=C1)(=O)=O)(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)